|
Purpose of the guideline：
|
In order to implement the Opinions of the General Office of the State Council on Strengthening the Performance Assessment of Level III Public Hospitals, and to further strengthen the management of clinical rational use of drugs in China, in accordance with the Working Procedures for the Adjustment of the Catalogue of Drugs under the National Key Monitoring of Rational Use of Drugs (GYH [2021] No. 474), On January 13, 2023, the National Health Commission determined the Second Batch of National Key Monitoring and Rational Drug Use Catalogue (hereinafter referred to as the Catalogue). The Catalogue mainly includes adjuvant drugs, anti-tumor drugs, anti-microbial drugs, proton pump inhibitors, glucocorticoids, parenteral nutrition drugs, etc. With the goal of standardizing clinical drug use behavior and promoting rational drug use, the Branch of Clinical Pharmacy of the Chinese Medical Association has formulated guidelines for good clinical application of 30 drugs included in the Catalog, including omeprazole, human serum albumin, cefoperazone sulbactam, and edaravone, to clarify the conditions and principles of clinical application, and to strengthen the supervision of rational drug use, so as to promote the continuous improvement of clinical rational drug use. |
